Upstream / Downstream

Explore pathways related to this product.

Antibody Guarantee

CST Antibody Performance Guarantee

LEARN MORE  

Questions?

Find answers on our FAQs page.

ANSWERS  

Visit PhosphoSitePlus®

PTM information and tools available.

LEARN MORE

REACTIVITY
H
Product Includes Volume Solution Color
p53 Rabbit mAb Coated Microwells  
P-p53 (S15) DetectionAb 11 ml Green
Anti-mouse IgG, HRP-linked Antibody 11 ml Red
TMB Substrate 7004 11 ml Colorless
STOP Solution 7002 11 ml Colorless
Sealing Tape 2 sheets
ELISA Wash Buffer (20X) 25 ml Colorless
ELISA Sample Diluent 25 ml Blue
Cell Lysis Buffer (10X) 9803 15 ml Yellowish

Order Details

Custom Ordering Details: Product is assembled upon order to ensure maximum activity. United States: Please allow up to two weeks for your order to be processed and shipped. Outside of the United States: Please allow up to three weeks, depending on the country, for your order to be processed and shipped. When ordering five or more kits, please contact us for processing time and pricing at sales@cellsignal.com.
Page

ELISA Colormetric

NOTE: Refer to product-specific datasheets or product webpage for assay incubation temperature.

A. Solutions and Reagents

NOTE: Prepare solutions with reverse osmosis deionized (RODI) or equivalent grade water.

  1. 20X Phosphate Buffered Saline (PBS): (#9808) To prepare 1 L PBS: add 50 ml 10X PBS to 950 ml dH2O, mix.
  2. Bring all microwell strips to room temperature before use.
  3. Prepare 1X Wash Buffer by diluting 20X Wash Buffer (included in each PathScan® Sandwich ELISA Kit) in dH2O.
  4. 1X Cell Lysis Buffer: 10X Cell Lysis Buffer (#9803): To prepare 10 ml of 1X Cell Lysis Buffer, add 1 ml of 10X Cell Lysis Buffer to 9 ml of dH2O, mix. Buffer can be stored at 4°C for short-term use (1–2 weeks).

    Recommended: Add 1 mM phenylmethylsulfonyl fluoride (PMSF) (#8553) immediately before use.

    NOTE: Refer to product-specific datasheet or webpage for lysis buffer recommendation.

  5. TMB Substrate: (#7004).
  6. STOP Solution: (#7002).

B. Preparing Cell Lysates

For adherent cells

  1. Aspirate media when the culture reaches 80–90% confluence. Treat cells by adding fresh media containing regulator for desired time.
  2. Remove media and rinse cells once with ice-cold 1X PBS.
  3. Remove PBS and add 0.5 ml ice-cold 1X cell lysis buffer plus 1 mM PMSF to each plate (10 cm diameter) and incubate the plate on ice for 5 min.
  4. Scrape cells off the plate and transfer to an appropriate tube. Keep on ice.
  5. Sonicate lysates on ice.
  6. Microcentrifuge for 10 min (x14,000 rpm) at 4°C and transfer the supernatant to a new tube. The supernatant is the cell lysate. Store at -80°C in single-use aliquots.

For suspension cells

  1. Remove media by low speed centrifugation (~1,200 rpm) when the culture reaches 0.5–1.0 x 106 viable cells/ml. Treat cells by adding fresh media containing regulator for desired time.
  2. Collect cells by low speed centrifugation (~1,200 rpm) and wash once with 5–10 ml ice-cold 1X PBS.
  3. Cells harvested from 50 ml of growth media can be lysed in 2.0 ml of 1X cell lysis buffer plus 1 mM PMSF.
  4. Sonicate lysates on ice.
  5. Microcentrifuge for 10 min (x14,000 rpm) at 4°C and transfer the supernatant to a new tube. The supernatant is the cell lysate. Store at -80°C in single-use aliquots.

C. Test Procedure

  1. After the microwell strips have reached room temperature, break off the required number of microwells. Place the microwells in the strip holder. Unused microwells must be resealed in the storage bag and stored at 4°C immediately.
  2. Cell lysates can be undiluted or diluted with sample diluent (supplied in each PathScan® Sandwich ELISA Kit, blue color). Individual datasheets or product webpage for each kit provide information regarding an appropriate dilution factor for lysates and kit assay results.
  3. Add 100 µl of each undiluted or diluted cell lysate to the appropriate well. Seal with tape and press firmly onto top of microwells. Incubate the plate for 2 hr at 37°C. Alternatively, the plate can be incubated overnight at 4°C.
  4. Gently remove the tape and wash wells:
    1. Discard plate contents into a receptacle.
    2. Wash 4 times with 1X wash buffer, 200 µl each time per well.
    3. For each wash, strike plates on fresh paper towels hard enough to remove the residual solution in each well, but do not allow wells to completely dry at any time.
    4. Clean the underside of all wells with a lint-free tissue.
  5. Add 100 µl of detection antibody (green color) to each well. Seal with tape and incubate the plate at 37°C for 1 hr.
  6. Repeat wash procedure (Section C, Step 4).
  7. Add 100 µl of HRP-linked secondary antibody (red color) to each well. Seal with tape and incubate the plate for 30 min at 37°C.
  8. Repeat wash procedure (Section C, Step 4).
  9. Add 100 µl of TMB substrate to each well. Seal with tape and incubate the plate for 10 min at 37°C or 30 min at 25°C.
  10. Add 100 µl of STOP solution to each well. Shake gently for a few seconds.

    NOTE: Initial color of positive reaction is blue, which changes to yellow upon addition of STOP solution.

  11. Read results
    1. Visual Determination: Read within 30 min after adding STOP solution.
    2. Spectrophotometric Determination: Wipe underside of wells with a lint-free tissue. Read absorbance at 450 nm within 30 min after adding STOP solution.

posted June 2005

revised November 2013

protocol id: 21

Product Description

CST's PathScan® Phospho-p53 (Ser15) Sandwich ELISA Kit is a solid phase sandwich enzyme-linked immunosorbent assay (ELISA) that detects endogenous levels of Phospho-p53 (Ser15) protein. A p53 Rabbit mAb has been coated onto the microwells. After incubation with cell lysates, both nonphospho- and phospho-p53 proteins are captured by the coated antibody. Following extensive washing, a phospho-p53 (Ser15) Mouse mAb is added to detect the captured phospho-p53 protein. Anti-mouse IgG, HRP-linked antibody is then used to recognize the bound detection antibody. HRP substrate, TMB, is added to develop color. The magnitude of optical density for this developed color is proportional to the quantity of phospho-p53 protein.

Antibodies in kit are custom formulations specific to kit.


Specificity / Sensitivity

CST's PathScan® Phospho-p53 (Ser15) Sandwich ELISA Kit detects endogenous levels of Phospho-p53 (Ser15) protein. Using this Sandwich ELISA Kit #7365, a significant induction of phospho-p53 (Ser15) in HT-29 cells treated with UV can be detected. However, the level of total p53 (phospho- and non-phospho), detected by PathScan® Total p53 Sandwich ELISA Kit #7370, remains unchanged (Figure 1). This kit detects proteins from the indicated species, as determined through in-house testing, but may also detect homologous proteins from other species.


Species Reactivity: Human

The p53 tumor suppressor protein plays a major role in cellular response to DNA damage and other genomic aberrations. Activation of p53 can lead to either cell cycle arrest and DNA repair or apoptosis (1). p53 is phosphorylated at multiple sites in vivo and by several different protein kinases in vitro (2,3). DNA damage induces phosphorylation of p53 at Ser15 and Ser20 and leads to a reduced interaction between p53 and its negative regulator, the oncoprotein MDM2 (4). MDM2 inhibits p53 accumulation by targeting it for ubiquitination and proteasomal degradation (5,6). p53 can be phosphorylated by ATM, ATR, and DNA-PK at Ser15 and Ser37. Phosphorylation impairs the ability of MDM2 to bind p53, promoting both the accumulation and activation of p53 in response to DNA damage (4,7). Chk2 and Chk1 can phosphorylate p53 at Ser20, enhancing its tetramerization, stability, and activity (8,9). p53 is phosphorylated at Ser392 in vivo (10,11) and by CAK in vitro (11). Phosphorylation of p53 at Ser392 is increased in human tumors (12) and has been reported to influence the growth suppressor function, DNA binding, and transcriptional activation of p53 (10,13,14). p53 is phosphorylated at Ser6 and Ser9 by CK1δ and CK1ε both in vitro and in vivo (13,15). Phosphorylation of p53 at Ser46 regulates the ability of p53 to induce apoptosis (16). Acetylation of p53 is mediated by p300 and CBP acetyltransferases. Inhibition of deacetylation suppressing MDM2 from recruiting HDAC1 complex by p19 (ARF) stabilizes p53. Acetylation appears to play a positive role in the accumulation of p53 protein in stress response (17). Following DNA damage, human p53 becomes acetylated at Lys382 (Lys379 in mouse) in vivo to enhance p53-DNA binding (18). Deacetylation of p53 occurs through interaction with the SIRT1 protein, a deacetylase that may be involved in cellular aging and the DNA damage response (19).


1.  Chehab NH et al. (1999) Proc Natl Acad Sci U S A 96, 13777–82

2.  Levine, A.J. (1997) Cell 88, 323-31.

3.  Meek, D.W. (1994) Semin. Cancer Biol. 5, 203-210.

4.  Milczarek, G.J. et al. (1997) Life Sci. 60, 1-11.

5.  Shieh, S.Y. et al. (1997) Cell 91, 325-334.

6.  Honda, R. et al. (1997) FEBS Lett. 420, 25-27.

7.  Tibbetts, R.S. et al. (1999) Genes Dev. 13, 152-157.

8.  Shieh, S.Y. et al. (1999) EMBO J. 18, 1815-1823.

9.  Hirao, A. et al. (2000) Science 287, 1824-1827.

10.  Hao, M. et al. (1996) J. Biol. Chem. 271, 29380-29385.

11.  Lu, H. et al. (1997) Mol. Cell. Biol. 17, 5923-5934.

12.  Ullrich, S.J. et al. (1993) Proc. Natl. Acad. Sci. USA 90, 5954-5958.

13.  Kohn, K.W. (1999) Mol. Biol. Cell 10, 2703-2734.

14.  Lohrum, M. and Scheidtmann, K.H. (1996) Oncogene 13, 2527-2539.

15.  Sakaguchi, K. et al. (1998) Genes Dev 12, 2831-41.

16.  Knippschild, U. et al. (1997) Oncogene 15, 1727-1736.

17.  Oda, K. et al. (2000) Cell 102, 849-862.

18.  Ito, A. et al. (2001) EMBO J. 20, 1331-1340.

19.  Solomon, J.M. et al. (2006) Mol. Cell. Biol. 26, 28-38.


Entrez-Gene Id 7157
Swiss-Prot Acc. P04637

Protein Specific References

Chehab NH et al. (1999) Proc Natl Acad Sci U S A 96, 13777–82

Buschmann T et al. (2000) Cancer Res 60, 896–900

Chehab NH et al. (2000) Genes Dev 14, 278–88

Persons DL et al. (2000) J Biol Chem 275, 35778–85

Vaziri H et al. (2001) Cell 107, 149–59

Minamoto T et al. (2001) Oncogene 20, 3341–7

Stewart ZA et al. (2001) Oncogene 20, 113–24

Bean LJ and Stark GR (2001) Oncogene 20, 1076–84

Xie S et al. (2001) J Biol Chem 276, 43305–12

Xie S et al. (2001) J Biol Chem 276, 36194–9

Kim SJ et al. (2002) J Biol Chem 277, 33501–8

Bulavin DV et al. (2002) Nat Genet 31, 210–5

Shono T et al. (2002) Cancer Res 62, 1069–76

Adamson AW et al. (2002) J Biol Chem 277, 38222–9

Hase H et al. (2002) J Biol Chem 277, 46950–8

Bischof O et al. (2002) EMBO J 21, 3358–69

Qin JZ et al. (2002) Oncogene 21, 2991–3002

Hofmann TG et al. (2002) Nat Cell Biol 4, 1–10

Chouinard N et al. (2002) Biochem J 365, 133–45

Shiseki M et al. (2003) Cancer Res 63, 2373–8

Chen K et al. (2003) J Biol Chem 278, 39527–33

Sengupta S et al. (2003) EMBO J 22, 1210–22

Urban G et al. (2003) J Biol Chem 278, 9747–53

Oguchi K et al. (2003) Blood 101, 3622–7

Hideshima T et al. (2003) Blood 101, 1530–4

Lindström MS and Wiman KG (2003) Oncogene 22, 4993–5005

Hofseth LJ et al. (2003) Proc Natl Acad Sci U S A 100, 143–8

Wang C and Chen J (2003) J Biol Chem 278, 2066–71

Matsuoka M et al. (2003) Environ Health Perspect 111, 509–12

Yanamadala S and Ljungman M (2003) Mol Cancer Res 1, 747–54

Möller A et al. (2003) Cancer Res 63, 4310–4

Goudelock DM et al. (2003) J Biol Chem 278, 29940–7

Louria-Hayon I et al. (2003) J Biol Chem 278, 33134–41

Tritarelli A et al. (2004) Mol Biol Cell 15, 3751–7

Mroz RM et al. (2004) Am J Respir Cell Mol Biol 30, 564–8

Rui Y et al. (2004) EMBO J 23, 4583–94

Li Y et al. (2004) Oncogene 23, 7355–65

Vaghefi H and Neet KE (2004) Oncogene 23, 8078–87

Nair VD et al. (2004) J Biol Chem 279, 27494–501

Takagi M et al. (2004) Blood 103, 283–90

Ito K et al. (2004) Cancer Res 64, 1071–8

Koutsodontis G and Kardassis D (2004) Oncogene 23, 9190–200

Jackson MW et al. (2004) Oncogene 23, 4477–87

Dohoney KM et al. (2004) Oncogene 23, 49–57

Thompson T et al. (2004) J Biol Chem 279, 53015–22

Yeh PY et al. (2004) Oncogene 23, 3580–8

Komiyama S et al. (2004) Biochem Biophys Res Commun 323, 816–22

Soubeyrand S et al. (2004) Eur J Biochem 271, 3776–84

Ou YH et al. (2005) Mol Biol Cell 16, 1684–95

Feki A et al. (2005) Oncogene 24, 3726–36

Li Z et al. (2005) J Biol Chem 280, 16843–50

Di Stefano V et al. (2005) Oncogene 24, 5431–42

Hershko T et al. (2005) Cell Death Differ 12, 377–83

Mayo LD et al. (2005) J Biol Chem 280, 25953–9

Wesierska-Gadek J et al. (2005) Mol Cancer Ther 4, 113–24

Wang L et al. (2005) Oncogene 24, 3020–7

Zhao Y et al. (2006) Mol Cell Biol 26, 2782–90

Gresko E et al. (2006) EMBO J 25, 1883–94

Ichwan SJ et al. (2006) Oncogene 25, 1216–24

Knights CD et al. (2006) J Cell Biol 173, 533–44

Moiseeva O et al. (2006) Mol Biol Cell 17, 1583–92

Zeng PY and Berger SL (2006) Cancer Res 66, 10701–8

Li AG et al. (2006) Mol Cell 23, 575–87

Yoshida K et al. (2006) J Biol Chem 281, 5734–40

Li DW et al. (2006) Oncogene 25, 3006–22

Fraser M et al. (2006) Oncogene 25, 2203–12

Paulsen MT et al. (2006) Mol Cancer 5, 25

Singh K et al. (2007) PLoS One 2, e660

Nag A et al. (2007) J Biol Chem 282, 8812–20

Li HH et al. (2007) EMBO J 26, 402–11

Li Q et al. (2007) Cancer Res 67, 66–74

Taira N et al. (2007) Mol Cell 25, 725–38

Lambrot R et al. (2007) J Clin Endocrinol Metab 92, 2632–9

Ivanov GS et al. (2007) Mol Cell Biol 27, 6756–69

Nakanishi M et al. (2007) J Biol Chem 282, 22993–3004

Liu Y et al. (2007) J Biol Chem 282, 2505–11

Derheimer FA et al. (2007) Proc Natl Acad Sci U S A 104, 12778–83

Lee JH et al. (2007) J Cell Sci 120, 2259–71

Mantovani F et al. (2007) Nat Struct Mol Biol 14, 912–20

Wang H et al. (2008) J Biol Chem 283, 2564–74

Sun L et al. (2008) J Exp Clin Cancer Res 27, 35

Chang PC and Li M (2008) J Virol 82, 278–90

Lin T et al. (2008) Toxicology 247, 145–53

Chen JJ et al. (2008) J Immunol 180, 8030–9

Shouse GP et al. (2008) Mol Cell Biol 28, 448–56

Kitagawa M et al. (2008) Mol Cell 29, 217–31

Habold C et al. (2008) J Cell Mol Med 12, 607–21

Zhu H et al. (2008) Int J Cancer 123, 2741–9

Yamaguchi H et al. (2009) J Biol Chem 284, 11171–83

Wang Z et al. (2009) Pharm Res 26, 1140–8

Bar JK et al. (2009) Int J Gynecol Cancer 19, 1322–8

Nishimura T et al. (2009) J Biol Chem 284, 36442–52

Puca R et al. (2009) Mol Cancer 8, 85

Yadavilli S et al. (2009) J Biochem Mol Toxicol 23, 373–86

Baxter EW and Milner J (2010) J Neurooncol 97, 373–82

Fraser JA et al. (2010) J Biol Chem 285, 37773–86

Fraser JA et al. (2010) J Biol Chem 285, 37762–72

Shang X et al. (2010) Oncogene 29, 4938–46

Chen X et al. (2010) J Biol Chem 285, 12823–30

Kawano T et al. (2010) Int J Oncol 37, 787–95

Moehlenbrink J et al. (2010) Cancer Lett 292, 119–24

Venerando A et al. (2010) Cell Mol Life Sci 67, 1105–18

Puca R et al. (2010) Free Radic Biol Med 48, 1338–46

Marchenko ND et al. (2010) Cell Death Differ 17, 255–67

Aranha MM et al. (2011) PLoS One 6, e21396

Muñoz-Fontela C et al. (2011) Cell Cycle 10, 3701–5

Wu L et al. (2011) J Biol Chem 286, 2236–44

Ozeki C et al. (2011) J Biol Chem 286, 18251–60

Mellert HS et al. (2011) J Biol Chem 286, 4264–70

Valbuena A et al. (2011) PLoS One 6, e17320

Xu S et al. (2011) J Cardiovasc Pharmacol 58, 263–71

Seo SK et al. (2011) J Thorac Oncol 6, 1313–9

Savelyeva I and Dobbelstein M (2011) Oncogene 30, 865–75

Wu ZZ et al. (2011) J Cell Physiol 226, 2415–28

Smeenk L et al. (2011) PLoS One 6, e17574

Grison A et al. (2011) Proc Natl Acad Sci U S A 108, 17979–84

Gully CP et al. (2012) Proc Natl Acad Sci U S A 109, E1513–22

Wang H et al. (2012) DNA Repair (Amst) 11, 146–56

Xu S et al. (2013) Cell Res 23, 423–35

Chan C et al. (2013) Mol Cell Biol 33, 485–97

Thakur BK et al. (2013) Int J Cancer 132, 766–74

Yang Y et al. (2013) J Biol Chem 288, 529–39


For Research Use Only. Not For Use In Diagnostic Procedures.
Cell Signaling Technology® is a trademark of Cell Signaling Technology, Inc.
PathScan® is a trademark of Cell Signaling Technology, Inc.